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During  the  past  half  century,  excessive/misplaced  iron  has 
been observed to be a risk factor for an increasing number and 
diversity of disease conditions. An extensive list of conditions 
and of the types of iron association were published in early 2008. 
Within the subsequent year, four additional disorders have been 
recognized to be enhanced by iron: aging muscle atrophy, viral 
replication,  rosacea  and  pulmonary  alveolar  proteinosis.  This 
paper adds new data and emphasis on these disorders as entities 
associated with increased iron load and toxicity.
A  review  written  early  in  2008  contained  an  extensive  list 
of diseases for which excessive and/or misplaced iron has been 
reported to be a causative or associated risk factor.1 The metal is 
toxic by catalyzing generation of hydroxyl radicals that intensify 
oxidative stress as well as by serving as a growth-essential nutrient 
for invading microbial and neoplasmic cells.
In the subsequent twelve months following submission of the 
manuscript, four additional conditions in which iron is toxic have 
been described: (a) intensification of aging muscle atrophy,2 (b) 
increased  replication  of  human  immunodeficiency  virus  (HIV) 
and hepatitis C virus (HCV),3 (c) enhancement of rosacea,4 and 
(d) augmentation of pulmonary alveolar proteinosis (PAP).5 In this 
paper, the previously published tables of iron-related conditions 
and of the types of iron association are expanded to include these 
four conditions.
In  the  report  on  muscle  atrophy,  non-heme  iron  levels  in 
gastrocnemius muscle in male rats increased by 233% between six 
and thirty months of age.2 Abundance of mRNA transferrin recep-
tor-1 decreased by 80%. In related research in the same laboratory, 
non-heme iron and RNA oxidation increased significantly with age 
in quadriceps-derived subsarcolemma mitochondria.6 In a third 
related study, in rats between 29 and 37 months of age, non-heme 
iron in gastrocnemius muscle increased by 200% with an accom-
panying significant increase in oxidized RNA7 These changes were 
associated with evidence of sarcopenia; that is, decreased muscle 
mass and grip.
Although iron is not a component of viruses, infected host cells 
apparently need the metal to synthesize viral particles. During the 
past several decades, it has become manifest that one of the dangers 
of  excessive  iron  is  its  ability  to  favor  animal  viral  infections.8 
The importance of iron in HIV infection has received particular 
attention.9 The multi-faceted molecular sites of action of iron in 
synthesis of HIV, as well as of HCV, are now being compiled.3 Of 
special interest are indications that viruses can manipulate iron 
homeostasis so as to ensure their replication in host cells.
Rosacea  is  a  common  chronic  light-sensitive  inflammatory 
skin disease. In this inquiry, peroxide and antioxidant potential of 
serum as well as of skin cell ferritin were assayed.4 Serum peroxide 
levels were higher and total anti-oxidant potential was lower in 
patients than in healthy controls (p < 0.05). The number of ferritin 
positive cells was higher (p < 0.001) in patient samples especially in 
those with severe disease. Ultraviolet irradiation of skin plus skin 
cell iron accelerated development of photo-sensitization, photo-
aging and skin cancer.10 It will be of interest to directly measure 
iron deposits in rosacea cells.
In the investigation on PAP, bronchoalveolar lavage samples of 
20 patients were compared with those of 20 healthy volunteers.5 
Concentrations of iron, transferrin, transferrin receptor, lactoferrin 
and ferritin were significantly elevated in PAP relative to healthy 
persons. In contrast, quantities of ascorbate, glutathione and urate 
were significantly depressed in PAP patients, indicative of anti-
oxidant depletion. The results suggest an iron-catalyzed oxidative 
stress in the maintenance of PAP.
Similar alterations in pulmonary iron homeostasis have been 
observed in several other chronic lung diseases.11
The list of iron-associated diseases, whose compilation began 
25 years ago,12 continues to grow (Tables 1 and 2). Recognition of 
the toxicity of iron is stimulating research efforts to develop iron 
chelator drugs that might be able to remove the metal from specific 
disease sites.13,14
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Table 1    Conditions for which excessive/misplaced iron 
can be a risk factor
Aging  Infectious  Ophthalmic
muscle atrophy  bacterial, fungal &  macular degeneration 
  protozoan infections 
Cardiovascular  viral infections: HIV, HCV  Orthopedic
atherosclerosis    gout
cardiomyopathy  Neurologic  hemophilic
hypertension  ALS  synovitis
ischemic stroke  Alzheimer  osteoarthritis
venous leg ulcer  depression  osteoporosis
  Friedreich ataxia 
Dermal  Huntington  Otologic
porphyria  multiple sclerosis  aminoglycoside
cutanea tarda  Parkinson  toxicity
rosacea  PKAN 
  prion disease  Pediatric & Neonatal
Endocrine    Down syndrome
diabetes  Obstetric  epilepsy 
endometriosis  neonatal  sudden infant death
growth deficiency  hemochromatosis   
hypogonadism  pre-eclampsia  Pulmonary
hypothyroidism    alveolar proteinosis
  Oncologic  cystic fibrosis
Hepatic  breast  ozone lung injury
cirrhosis  colorectal  pneumoconiosis
steatohepatitis  esophageal  Renal
viral hepatitis  hepatic  aminoglycoside &
  Kaposi sarcoma  vancomycin toxicity
  leukemia 
  lung 
Modifed from Table 3 (Weinberg et al.)1.
Table 2  Association of iron with morbidity
•Iron, by itself, has been observed to initiate the disease
  cardiomyopathy 
  growth deficiency 
  hemophilic synovitis 
  hypogonadism 
  lung cancer 
  osteoporosis 
  pneumoconiosis
•Iron can be a cofactor in promoting the disease
  Alzheimer 
  atherosclerosis 
  bacterial infections 
  diabetes 
  endometriosis 
  esophageal adenocarcinoma 
  fungal & protozoan infections 
  gout 
  hepatoma 
  multiple sclerosis 
  osteoarthritis 
  oto- & renal toxicity 
  ozone lung injury 
  pulmonary alveolar proteinosis 
  viral infections
•Iron deposits are observed in disease-associated tissue sites
  basal ganglia in PKAN 
  hepatocytes in cirrhosis, steatohepatitis & viral 
  hepatitis 
  mitochondria in Friedreich ataxia 
  pulmonary secretions in cystic fibrosis 
  retina in macular degeneration 
  skin cells in rosacea 
  skeletal muscle in aging 
  substantia nigra in Parkinson 
  thyroid in hypothyroidism
•Body iron loading is associated with above normal incidence of morbidity
  ALS 
  breast cancer 
  colorectal cancer 
  depression 
  Down syndrome 
  epilepsy 
  hypertension 
  ischemic stroke 
  leukemia 
  pre-eclampsia 
  porphryia cutanea tarda 
  prion disease 
  sudden infant death syndrome
•Maternal antibodies can impair fetal iron metabolism
  fetal or neonatal death in neonatal hemochromatosis
Modified from Table 4 (Weinberg et al.)1.
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